Periostin activates integrin α5β1 through a PI3K/AKT-dependent, pathway in invasion of cholangiocarcinoma

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1110-1118

  Utispan, Kusumawadee ^a,c   Sonongbua, Jumaporn ^b   Thuwajit, Peti ^b   Chau In, Siri ^a,c   Pairojkul, Chawalit ^a,c   Wongkham, Sopit ^a   Thuwajit, Chanitra ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma; Fibroblast; Integrin; Invasion; Periostin; PI3K AKT

Indexed keywords

ALPHA6BETA4 INTEGRIN; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR RUNX2; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIBODIES, BLOCKING; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FIBROBLASTS; HUMANS; INTEGRIN ALPHA5BETA1; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84864981474     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1530     Document Type: Article

References (50)

1. Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15, 2005.
2. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S and Parkin DM: Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health 9: 588-594, 2004.
3. Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M and Glaser SS: Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol 14: 2986-2989, 2008.
4. Franco OE, Shaw AK, Strand DW and Hayward SW: Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21: 33-39, 2010.
5. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T and Thuwajit C: Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 21: 957-969, 2009.
6. Utispan K, Thuwajit P, Abiko Y, et al: Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer 9: 13, 2010.
7. Sirica AE, Campbell DJ and Dumur CI: Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 27: 276-284, 2011.
8. Terada T, Makimoto K, Terayama N, Suzuki Y and Nakanuma Y: Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol 24: 706-712, 1996.
9. Darby IA, Vuillier-Devillers K, Pinault E, et al: Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. Cancer Microenviron 4: 73-91, 2010.
10. Dumur CI, Campbell DJ, DeWitt JL, Oyesanya RA and Sirica AE: Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp Mol Pathol 89: 227-235, 2010.
11. Ruan K, Bao S and Ouyang G: The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 66: 2219-2230, 2009.
12. Erkan M, Kleeff J, Gorbachevski A, et al: Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132: 1447-1464, 2007.
13. Fukushima N, Kikuchi Y, Nishiyama T, Kudo A and Fukayama M: Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol 21: 1044-1053, 2008.
14. Li JS, Sun GW, Wei XY and Tang WH: Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol 13: 5261-5266, 2007.
15. Puglisi F, Puppin C, Pegolo E, et al: Expression of periostin in human breast cancer. J Clin Pathol 61: 494-498, 2008.
16. Puppin C, Fabbro D, Dima M, et al: High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. J Endocrinol 197: 401-408, 2008.
17. Takanami I, Abiko T and Koizumi S: Expression of periostin in patients with non-small cell lung cancer: correlation with angiogenesis and lymphangiogenesis. Int J Biol Markers 23: 182-186, 2008.
18. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY and Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 62: 5358-5364, 2002.
19. Kudo Y, Ogawa I, Kitajima S, et al: Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 66: 6928-6935, 2006.
20. Bao S, Ouyang G, Bai X, et al: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5: 329-339, 2004.
21. Baril P, Gangeswaran R, Mahon PC, et al: Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 26: 2082-2094, 2007.
22. Li G, Jin R, Norris RA, et al: Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis 208: 358-365, 2010.
23. Shao R, Bao S, Bai X, et al: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 24: 3992-4003, 2004.
24. Yan W and Shao R: Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem 281: 19700-19708, 2006.
25. Sripa B, Leungwattanawanit S, Nitta T, et al: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 11: 3392-3397, 2005.
26. Maruyama M, Kobayashi N, Westerman KA, et al: Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation 77: 446-451, 2004.
27. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S and Gronholm M: Regulation of integrin activity and signalling. Biochim Biophys Acta 1790: 431-444, 2009.
28. Angeli F, Koumakis G, Chen MC, Kumar S and Delinassios JG: Role of stromal fibroblasts in cancer: promoting or impeding? Tumour Biol 30: 109-120, 2009.
29. Qiu W, Hu M, Sridhar A, et al: No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40: 650-655, 2008.
30. Pietras K and Ostman A: Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316: 1324-1331, 2010.
31. Gonda TA, Varro A, Wang TC and Tycko B: Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol 21: 2-10, 2010.
32. Rasanen K and Vaheri A: Activation of fibroblasts in cancer stroma. Exp Cell Res 316: 2713-2722, 2010.
33. Rosenthal E, McCrory A, Talbert M, Young G, Murphy-Ullrich J and Gladson C: Elevated expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol Carcinog 40: 116-121, 2004.
34. Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N and Rotter V: Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res 7: 1212-1223, 2009.
35. Volpes R, van den Oord JJ and Desmet VJ: Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol 142: 1483-1492, 1993.
36. Enjoji M, Sakai H, Nakashima M and Nawata H: Integrins: utility as cell type- and stage-specific markers for hepatocellular carcinoma and cholangiocarcinoma. In Vitro Cell Dev Biol Anim 34: 25-27, 1998.
37. Patsenker E, Wilkens L, Banz V, et al: The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol 52: 362-369, 2010.
38. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002.
39. Ouyang G, Liu M, Ruan K, Song G, Mao Y and Bao S: Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett 281: 213-219, 2009.
40. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
41. Sarker D, Reid AH, Yap TA and de Bono JS: Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15: 4799-4805, 2009.
42. Yadav V and Denning MF: Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog 50: 346-352, 2011.
43. Roman J, Ritzenthaler JD, Roser-Page S, Sun X and Han S: alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol 43: 684-691, 2010.
44. Mierke CT, Frey B, Fellner M, Herrmann M and Fabry B: Integrin alpha5beta1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci 124: 369-383, 2011.
45. Morozevich G, Kozlova N, Cheglakov I, Ushakova N and Berman A: Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle 8: 2219-2225, 2009.
46. Castillo SS, Brognard J, Petukhov PA, et al: Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 64: 2782-2792, 2004.
47. Kyutoku M, Taniyama Y, Katsuragi N, et al: Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med 28: 181-186, 2011.
48. Almokadem S and Belani CP: Volociximab in cancer. Expert Opin Biol Ther 12: 251-257, 2012.
49. Li Z, Tan F, Liewehr DJ, Steinberg SM and Thiele CJ: In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst 102: 758-770, 2010.
50. Pal SK, Reckamp K, Yu H and Figlin RA: Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355-1366, 2010.